Stockscreener 앱 받기
15.82
4.08%
0.62
시간 외 거래:
15.82
전일 마감가:
$15.20
열려 있는:
$15.26
하루 거래량:
1.05M
Relative Volume:
0.87
시가총액:
$796.38M
수익:
-
순이익/손실:
$-156.39M
주가수익비율:
-4.2873
EPS:
-3.69
순현금흐름:
$-123.06M
1주 성능:
+17.53%
1개월 성능:
+21.23%
6개월 성능:
+36.26%
1년 성능:
+22.92%
1일 변동 폭
$15.04
$15.85
1주일 범위
$13.47
$15.85
52주 변동 폭
$7.30
$16.32
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
KALV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
15.82 | 765.17M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-12-18 | 개시 | BofA Securities | Buy |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
Is KalVista Pharmaceuticals Inc. stock a smart retirement pickWeekly Stock Recap & Reliable Volume Spike Alerts - خودرو بانک
Aug Rallies: What is KalVista Pharmaceuticals Inc. s 5 year growth outlook2025 Big Picture & Capital Protection Trade Alerts - خودرو بانک
What analysts say about KalVista Pharmaceuticals Inc. stock2025 Risk Factors & Breakout Confirmation Trade Signals - خودرو بانک
Can KalVista Pharmaceuticals Inc. deliver consistent dividendsQuarterly Portfolio Summary & Long-Term Capital Growth Strategies - خودرو بانک
Can technical indicators confirm KalVista Pharmaceuticals Inc.’s reversalChart Signals & Safe Entry Point Alerts - Newser
KalVista Pharmaceuticals Inc. stock volume spike explainedGap Down & Real-Time Stock Entry Alerts - Newser
Does KalVista Pharmaceuticals (NASDAQ:KALV) Have A Healthy Balance Sheet? - 富途牛牛
Is KalVista Pharmaceuticals Inc. building a consolidation base2025 Earnings Surprises & Low Risk Entry Point Guides - Newser
What MACD and RSI say about KalVista Pharmaceuticals Inc.Analyst Downgrade & High Conviction Buy Zone Alerts - Newser
Is KalVista Pharmaceuticals (NASDAQ:KALV) A Risky Investment? - simplywall.st
Can volume confirm reversal in KalVista Pharmaceuticals Inc.2025 Market Trends & Low Drawdown Trading Techniques - Newser
Combining machine learning predictions for KalVista Pharmaceuticals Inc.Trend Reversal & Daily Volume Surge Signals - Newser
Evaluating KalVista Pharmaceuticals Inc. with trendline analysisMarket Volume Report & Risk Adjusted Swing Trade Ideas - Newser
Can KalVista Pharmaceuticals Inc. maintain sales growthEarnings Growth Summary & Stepwise Entry and Exit Trade Signals - خودرو بانک
KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025 - Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
KalVista Q1 Earnings On DeckWill Sebetralstat's EU Nod Be The Catalyst It Needs? - RTTNews
Institutional scanner results for KalVista Pharmaceuticals Inc.Wall Street Watch & High Accuracy Swing Entry Alerts - Newser
Applying Elliott Wave Theory to KalVista Pharmaceuticals Inc.Weekly Trade Review & Daily Chart Pattern Signal Reports - Newser
Short interest data insights for KalVista Pharmaceuticals Inc.July 2025 Action & Community Consensus Picks - Newser
What’s the recovery path for long term holders of KalVista Pharmaceuticals Inc.2025 Volatility Report & Free Weekly Watchlist of Top Performers - Newser
What is KalVista Pharmaceuticals Inc. s debt to equity ratioDip Buying & Safe Entry Point Identification - خودرو بانک
Price action breakdown for KalVista Pharmaceuticals Inc.Jobs Report & Verified Momentum Stock Ideas - Newser
How high can KalVista Pharmaceuticals Inc. stock goMarket Growth Review & Weekly Watchlist for Hot Stocks - Newser
Price momentum metrics for KalVista Pharmaceuticals Inc. explainedSwing Trade & Weekly Top Performers Watchlists - Newser
Chart based exit strategy for KalVista Pharmaceuticals Inc.2025 Top Decliners & AI Driven Stock Reports - Newser
How institutional ownership impacts KalVista Pharmaceuticals Inc. stock2025 Top Gainers & Consistent Profit Alerts - Newser
KALVISTA PHARMACEUTICALS Earnings Preview: Recent $KALV Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
KalVista Pharmaceuticals Inc. Recovers — But Is It Sustainable getLinesFromResByArray error: size == 0 - 강소기업뉴스
Analyzing recovery setups for KalVista Pharmaceuticals Inc. investorsTrade Volume Report & Technical Entry and Exit Tips - Newser
Real time social sentiment graph for AFRIWJuly 2025 Review & Technical Pattern Recognition Alerts - Newser
Sentiment analysis tools applied to KalVista Pharmaceuticals Inc.July 2025 Volume & Fast Gaining Stock Reports - Newser
Heatmap Data Shows High Activity in KalVista Pharmaceuticals Inc. Sector2025 Pullback Review & Growth Oriented Trading Recommendations - beatles.ru
How to build a dashboard for KalVista Pharmaceuticals Inc. stockWeekly Trade Analysis & Fast Moving Stock Trade Plans - Newser
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kalvista Pharmaceuticals Inc 주식 (KALV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Aug 25 '25 |
Sale |
13.42 |
1,954 |
26,223 |
132,052 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Aug 25 '25 |
Sale |
13.42 |
2,336 |
31,349 |
122,505 |
| Sweeny Nicole | Chief Commercial Officer |
Aug 22 '25 |
Sale |
13.22 |
1,864 |
24,647 |
28,771 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Aug 22 '25 |
Sale |
13.22 |
2,362 |
31,232 |
130,881 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Aug 22 '25 |
Sale |
13.22 |
10,940 |
144,657 |
386,858 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Aug 22 '25 |
Sale |
13.22 |
2,942 |
38,901 |
119,841 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Aug 18 '25 |
Sale |
13.19 |
2,649 |
34,932 |
129,493 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Aug 18 '25 |
Sale |
13.19 |
2,939 |
38,757 |
116,533 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Aug 18 '25 |
Sale |
13.19 |
4,409 |
58,141 |
374,548 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Jul 09 '25 |
Sale |
15.69 |
32,979 |
517,523 |
369,595 |
1.40%
자본화:
|
볼륨(24시간):